DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
This action is responsive to applicants’ amendment and response received August 14, 2026. Claims 1-15 and 17-23 are currently pending.
Claim Objections
Claim 13 objected to because of the following informalities: The claim should be rewritten for clarity. Appropriate correction is required.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
All rejections set forth in the previous action are withdrawn in view of applicants’ amendment and response.
Claims 1-8, and 17-23 are rejected under 35 U.S.C. 102a1 as being anticipated by Yamada et al, US 2022/0389279.
Yamada et al teach a CMP composition comprising 0.005% 3-triethoxysilylpropyl succinic anhydride, 0.2% citric acid, 0.01% polyacrylic acid, and the balance water wherein the composition has a pH of 3 and it polishes tungsten films (¶158, example 8). As this reference meets all material limitations of the claims at hand, the reference is anticipatory.
Claims 1-8, 17-21, and 23 are rejected under 35 U.S.C. 102a1 as being anticipated by Xu et al, US 2003/0205481.
Xu et al teach a silane solution comprising 0.005% vinyltrimethoxysilane, 0.0025% acetic acid, 0.0018% polyacrylic acid, and the balance water (¶37, example 5). As this reference meets all material limitations of the claims at hand, the reference is anticipatory.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claims 1-15 and 17-23 are rejected under 35 U.S.C. 103 as being unpatentable over Yamada et al, US 2022/0389279.
Yamada et al are relied upon as set forth above. Suitable organic acids of the reference include 2,4-hexadienoic acid (¶62) and preferred additives include histidine and arginine in an amount of 0.02% (examples 9 and 10). It would have been obvious for one of ordinary skill in the art to add typical CMP additives to the composition of example 8 with confidence of forming an effective CMP composition.
Conclusion
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHARLES I BOYER whose telephone number is (571)272-1311. The examiner can normally be reached M-S 10-430.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Angela Brown-Pettigrew can be reached at 5712722817. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/CHARLES I BOYER/Primary Examiner, Art Unit 1761